| pubmed-article:11323338 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11323338 | lifeskim:mentions | umls-concept:C0008059 | lld:lifeskim |
| pubmed-article:11323338 | lifeskim:mentions | umls-concept:C0002903 | lld:lifeskim |
| pubmed-article:11323338 | lifeskim:mentions | umls-concept:C0021270 | lld:lifeskim |
| pubmed-article:11323338 | lifeskim:mentions | umls-concept:C0152021 | lld:lifeskim |
| pubmed-article:11323338 | lifeskim:mentions | umls-concept:C0074414 | lld:lifeskim |
| pubmed-article:11323338 | lifeskim:mentions | umls-concept:C0036043 | lld:lifeskim |
| pubmed-article:11323338 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:11323338 | pubmed:dateCreated | 2001-4-27 | lld:pubmed |
| pubmed-article:11323338 | pubmed:abstractText | We tested the hypothesis that sevoflurane is a safer and more effective anesthetic than halothane during the induction and maintenance of anesthesia for infants and children with congenital heart disease undergoing cardiac surgery. With a background of fentanyl (5 microg/kg bolus, then 5 microg. kg(-1). h(-1)), the two inhaled anesthetics were directly compared in a randomized, double-blinded, open-label study involving 180 infants and children. Primary outcome variables included severe hypotension, bradycardia, and oxygen desaturation, defined as a 30% decrease in the resting mean arterial blood pressure or heart rate, or a 20% decrease in the resting arterial oxygen saturation, for at least 30 s. There were no differences in the incidence of these variables; however, patients receiving halothane experienced twice as many episodes of severe hypotension as those who received sevoflurane (P = 0.03). These recurrences of hypotension occurred despite an increased incidence of vasopressor use in the halothane-treated patients than in the sevoflurane-treated patients. Multivariate stepwise logistic regression demonstrated that patients less than 1 yr old were at increased risk for hypotension compared with older children (P = 0.0004), and patients with preoperative cyanosis were at increased risk for developing severe desaturation (P = 0.049). Sevoflurane may have hemodynamic advantages over halothane in infants and children with congenital heart disease. IMPLICATIONS: In infants and children with congenital heart disease, anesthesia with sevoflurane may result in fewer episodes of severe hypotension and less emergent drug use than anesthesia with halothane. | lld:pubmed |
| pubmed-article:11323338 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11323338 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11323338 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:11323338 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11323338 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11323338 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11323338 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11323338 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11323338 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11323338 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11323338 | pubmed:month | May | lld:pubmed |
| pubmed-article:11323338 | pubmed:issn | 0003-2999 | lld:pubmed |
| pubmed-article:11323338 | pubmed:author | pubmed-author:ReynoldsL MLM | lld:pubmed |
| pubmed-article:11323338 | pubmed:author | pubmed-author:HickeyR FRF | lld:pubmed |
| pubmed-article:11323338 | pubmed:author | pubmed-author:DeSilvaAA | lld:pubmed |
| pubmed-article:11323338 | pubmed:author | pubmed-author:ReddyV MVM | lld:pubmed |
| pubmed-article:11323338 | pubmed:author | pubmed-author:HanleyF LFL | lld:pubmed |
| pubmed-article:11323338 | pubmed:author | pubmed-author:CahalanM KMK | lld:pubmed |
| pubmed-article:11323338 | pubmed:author | pubmed-author:GregoryGG | lld:pubmed |
| pubmed-article:11323338 | pubmed:author | pubmed-author:CassorlaLL | lld:pubmed |
| pubmed-article:11323338 | pubmed:author | pubmed-author:Rouine-RappKK | lld:pubmed |
| pubmed-article:11323338 | pubmed:author | pubmed-author:RussellI AIA | lld:pubmed |
| pubmed-article:11323338 | pubmed:author | pubmed-author:Miller... | lld:pubmed |
| pubmed-article:11323338 | pubmed:author | pubmed-author:BaleaM CMC | lld:pubmed |
| pubmed-article:11323338 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11323338 | pubmed:volume | 92 | lld:pubmed |
| pubmed-article:11323338 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11323338 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11323338 | pubmed:pagination | 1152-8 | lld:pubmed |
| pubmed-article:11323338 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:11323338 | pubmed:meshHeading | pubmed-meshheading:11323338... | lld:pubmed |
| pubmed-article:11323338 | pubmed:meshHeading | pubmed-meshheading:11323338... | lld:pubmed |
| pubmed-article:11323338 | pubmed:meshHeading | pubmed-meshheading:11323338... | lld:pubmed |
| pubmed-article:11323338 | pubmed:meshHeading | pubmed-meshheading:11323338... | lld:pubmed |
| pubmed-article:11323338 | pubmed:meshHeading | pubmed-meshheading:11323338... | lld:pubmed |
| pubmed-article:11323338 | pubmed:meshHeading | pubmed-meshheading:11323338... | lld:pubmed |
| pubmed-article:11323338 | pubmed:meshHeading | pubmed-meshheading:11323338... | lld:pubmed |
| pubmed-article:11323338 | pubmed:meshHeading | pubmed-meshheading:11323338... | lld:pubmed |
| pubmed-article:11323338 | pubmed:meshHeading | pubmed-meshheading:11323338... | lld:pubmed |
| pubmed-article:11323338 | pubmed:meshHeading | pubmed-meshheading:11323338... | lld:pubmed |
| pubmed-article:11323338 | pubmed:meshHeading | pubmed-meshheading:11323338... | lld:pubmed |
| pubmed-article:11323338 | pubmed:meshHeading | pubmed-meshheading:11323338... | lld:pubmed |
| pubmed-article:11323338 | pubmed:meshHeading | pubmed-meshheading:11323338... | lld:pubmed |
| pubmed-article:11323338 | pubmed:meshHeading | pubmed-meshheading:11323338... | lld:pubmed |
| pubmed-article:11323338 | pubmed:meshHeading | pubmed-meshheading:11323338... | lld:pubmed |
| pubmed-article:11323338 | pubmed:meshHeading | pubmed-meshheading:11323338... | lld:pubmed |
| pubmed-article:11323338 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11323338 | pubmed:articleTitle | The safety and efficacy of sevoflurane anesthesia in infants and children with congenital heart disease. | lld:pubmed |
| pubmed-article:11323338 | pubmed:affiliation | Department of Anesthesia and Perioperative Care, Division of Pediatric Cardiac Surgery, University of California-San Francisco, 521 Parnassus Ave., C450, San Francisco, CA 94143-0648, USA. | lld:pubmed |
| pubmed-article:11323338 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11323338 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:11323338 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:11323338 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11323338 | lld:pubmed |
